✦ LIBER ✦

Rentech to license floating GTL technology

Publisher: Elsevier Science
Year: 2003
Weight: 31 KB
Volume: 2003
Category: Article
ISSN: 1351-4180
DOI: 10.1016/s1351-4180(03)00427-6

No coin nor oath required. For personal study only.

✦ Synopsis

R&D costs rose by 5% to DKR 713 M for 2002. The group generated profit of DKR 644 M after tax for 2002. Headquartered in Denmark, Novozymes A/S is a biotech-based world leader in enzymes and microorganisms for industrial use. Novozymes also applies its core competences in selected pharmaceutical areas.

📜 SIMILAR VOLUMES

Rentech in another GTL licensing move

📂 Article 📅 2003 🏛 Elsevier Science ⚖ 35 KB

are competitive and has joined up with Genencor to develop a bio-based route.

Rentech continues its GTL licensing spre

Rentech continues its GTL licensing spree

📂 Article 📅 2003 🏛 Elsevier Science ⚖ 33 KB

development and production of pharmaceutical intermediates. AHF integrates the introduction of versatile aldehyde functionality with the formation of a chiral centre. Dow's new generation of chiral bisphosphite ligands is claimed to expand the scope of the technology beyond the vinylarene substrates

Rentech issues update to shareholders on

Rentech issues update to shareholders on GTL project status

📂 Article 📅 2003 🏛 Elsevier Science ⚖ 39 KB

working on a filamentous fungus named Trichoderma to engineer a metabolic pathway that breaks down biomass into monosaccharides. The biomass-to-ethanol conversion process technology would be economically competitive if the enzymes' cost were within the $0.05-0.15/gal of ethanol range. A pilot plant

Rentech awarded sixteenth patent related

Rentech awarded sixteenth patent related to its GTL process

📂 Article 📅 2003 🏛 Elsevier Science ⚖ 33 KB

Rentech and Global Process Systems to fl

Rentech and Global Process Systems to float

📂 Article 📅 2002 🏛 Elsevier Science ⚖ 33 KB

1H 2002 (DKR 2508(DKR M in 1H 2001)). Net profit amounted to DKR 270 M, representing an increase of 3% for 1H 2002. During 1H 2002, volumes, prices, and product mix in the market increased sales by 10%, although lower exchange rates reduced sales by 2%. Sales of technical enzymes, etc rose by 5%; an

Whom to license patented technology

✍ Sang-Seung Yi 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

This paper examines the optimal licensing policy of a patent holder when potential licensees differ in their capacities in absorbing the patented technology. If two-part tariffs with non-negative royalties and fixed fees are feasible, the patent holder finds it optimal to license the strong firm exc